Toggle light / dark theme

The closest black hole to the Earth has been discovered just 1,000 light years away — near enough to see its companion stars with the naked eye on a clear night.

Located in the constellation of Telescopium, the hole forms part of a so-called ‘triple system — one named ‘HR 6819’ — with its two accompanying stars.

The presence of a hidden black hole in HR 6819 was discovered by researchers from the European Southern Observatory (ESO)’s La Silla Observatory in Chile.

A truck-sized asteroid has careened past Earth in one of the closest flybys ever recorded – but none of satellites scanning the skies to protect our planet saw the space rock coming.

The previously unseen asteroid, 2020 JJ, whizzed past at a distance of around 7,000 kilometers (4,350 miles) this week. In astronomical terms, that’s an incredibly close shave, and it makes it one of the closest passes of our planet ever recorded.

In a development that might worry those tasked with protecting Earth from being smashed by space objects, the asteroid was only discovered by the Mount Lemmon Survey in Arizona at almost exactly the time it reached its closest point to Earth.

Virgin Galactic reported first-quarter earnings and the stock is surging in premarket trading. People, it seems, can’t wait to leave Earth. That’s a good thing for the fledgling space-tourism company.

Virgin (ticker: SPCE) reported $238,000 in first-quarter sales. But sales and earnings don’t matter yet. Virgin is “presales” at this stage of its life. The company is working with aviation authorities to approve its spacecraft and its plans for ferrying customers to the edge of Earth’s atmosphere. It completed two test flights from its New Mexico spaceport in the first quarter.

But sales are coming. During the quarter, the company launched an initiative for tourist-astronauts to reserve a place in Galactic’s flight queue, attracting commitments for up to $100 million in sales.

“Putting matters of taste aside, X Æ A-12 is a wildly impractical name,” Wattenberg went on. “It’s not only hard to spell and remember and virtually unpronounceable; it’s not even easily typable and no forms or databases will accept it. It’s simply nonfunctional. If—and it’s a big if—this is their real name choice, it’s in a whole different class than other celebrity baby names that people object to on the basis of style. It fails at the basic job of being a contemporary American name.”

“Fails at the basic job of being a contemporary American name” would sound, to a lot of us, like failure. I doubt it would to Musk and Grimes. Perhaps the only answer for them was going to be a name that fails at being a name, and therefore deconstructs the concept of people having names in general. In that case, mission accomplished. Though, of course, there’s someone else who did it first.

“Magufuli, who holds a doctorate in chemistry, said the testers had randomly obtained several non-human samples on animals and fruits which included a sheep, a goat and a pawpaw and the results came out positive. The samples were given human names and ages and were submitted to the country’s National Referral Laboratory to test for coronavirus without the lab technicians knowing the true identity of the samples.”


Tanzania president John Magufuli is under mounting pressure from concerns around coronavirus.

Broad-spectrum antivirals are desirable, particularly in the context of emerging zoonotic infections for which specific interventions do not yet exist. Sheahan et al. tested the potential of a ribonucleoside analog previously shown to be active against other RNA viruses such as influenza and Ebola virus to combat coronaviruses. This drug was effective in cell lines and primary human airway epithelial cultures against multiple coronaviruses including SARS-CoV-2. Mouse models of SARS and MERS demonstrated that early treatment reduced viral replication and damage to the lungs. Mechanistically, this drug is incorporated into the viral RNA, inducing mutations and eventually leading to error catastrophe in the virus. In this manner, inducing catastrophe could help avoid catastrophe by stemming the next pandemic.

Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) has broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c bat-CoVs, as well as increased potency against a CoV bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC prodrug (β-d-N4-hydroxycytidine-5′-isopropyl ester), improved pulmonary function and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral, but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV.

Metamaterials, which are engineered to have properties not found in nature, have long been developed and studied because of their unique features and exciting applications. However, the physics behind their thermal emission properties have remained unclear to researchers—until now.

In a paper published in Physical Review Letters, Sheng Shen, an associate professor in Carnegie Mellon’s department of mechanical engineering, and his student Jiayu Li, a Ph.D. candidate, have created a new scale law to describe the thermal emission from metasurfaces and metamaterials.

“With this new scale law uncovering the underlying physics behind the collective thermal emission behavior of metamaterials, researchers could easily utilize existing design and optimization tools to achieve desired thermal emission properties from metamaterials, instead of blindly searching for the best solution through mapping the entire design space,” Li said.

Coronavirus disease 2019 (COVID-19) presents with a broad clinical spectrum, varying from asymptomatic infection to severe pneumonitis, leading to acute respiratory distress syndrome (ARDS) and death(Guan, et al 2020). Accumulating evidence suggests that in severe COVID-19, an acute hyperinflammatory syndrome characterised by fever, hypoxia and increased serum inflammatory markers, occurring 5–10 days from the first symptoms, is the major driver of morbidity and death(Zhou, et al 2020b). Hyperinflammation is not specific to COVID-19. Similar syndromes were previously described in respiratory disease associated with other coronaviruses, including the severe acute respiratory syndrome-coronavirus (SARS-CoV) in 2003 and Middle East respiratory syndrome-coronavirus (MERS-CoV) in 2012(Castilletti, et al 2005, Tseng, et al 2005).

This article is protected by copyright. All rights reserved.

I shared about this startup in January, now it’s hitting US Markets. The Israeli startup Sonovia, which sped up efforts to manufacture masks using its anti-pathogen fabric at the start of the coronavirus crisis in Israel, has launched commercial sales.


“When coronavirus started, we were an Israeli startup,” Dr. Jason Migdal, a research scientist with Sonovia, told The Jerusalem Post. “Now, we are a commercial business that is having success internationally.”

Sonovia developed an almost-permanent, ultrasonic, fabric-finishing technology for mechanical impregnation of zinc oxide nanoparticles into textiles.

“The technology is based upon a physical phenomenon called cavitation,” said Migdal. “Sound waves are used to physically infuse desired chemicals onto the structure area of materials, enhancing them with clinically proven antiviral and antibacterial properties.”

India’s recent move to curb foreign direct investment (FDI) from countries including China may stymie the expansion of Chinese technology giants in the country, leaving start-ups in the world’s second most populous nation scrambling for funding and hi-tech know-how, experts say.


The stakes of Chinese firms like Alibaba and Tencent in some of India’s most lucrative start-ups, such as Paytm and Dream11, may be threatened by new investment restrictions, experts say.